Overview of the Supreme Court’s review of skinny labeling in Amarin Inc. v. Hikma Pharm. USA, Inc., and its implications for generic drug makers, marketing, and inducement liability.
| less than a minute read
The Skinny Labeling Saga Continues

/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-11-19-18-23-09-165-6aff3e8d1748b264d5a55940.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-11-19-18-25-24-196-6aff3f146841ccf0c13e1db2.jpg)

